# Enlivex Announces the Dosing of the First Patient in a Randomized, Placebo-Controlled Phase I/II Trial Evaluating AllocetraTM in up to 46 Patients with Thumb Osteoarthritis
Canonical URL: https://biopharmsignal.com/news/ENLV/enlivex-announces-the-dosing-of-the-first-patient-in-a-randomized-placebo-controlled-phase-i-ii-trial-evaluating-allocetratm-in-up-to-46-patients-with-thumb-osteoarthritis
Ticker: ENLV
Company: Enlivex Therapeutics
Source: Enlivex Therapeutics
Published: 2024-06-24 08:00 EST
Original Source URL: https://www.pressviewer.com
## Summary

<div class="b2iNewsItemBodyDiv"><link type="text/css" rel="stylesheet" href="https://www.globenewswire.com/styles/gnw_nitf.css" /><p> <br /></p> <ul><li>First patient dosed with Allocetra<sup>TM</sup> in thumb osteoarthritis, a degenerative, debilitating and progressive disease that affects millions of people</li><li>T

## Article Body
First patient dosed with AllocetraTM in thumb osteoarthritis, a degenerative, debilitating and progressive disease that affects millions of people

Thumb osteoarthritis currently has no FDA-approved therapy and no effective long-term treatments

Ness-Ziona, Israel, June  24, 2024  (GLOBE NEWSWIRE)...
## Recent Company News
- 2026-07-29 13:00 EST — [Enlivex Management to Host Webinar to Discuss Capital Strategy, Rain Protocol Treasury Strategy, and Recent Clinical Milestones](https://biopharmsignal.com/news/ENLV/enlivex-management-to-host-webinar-to-discuss-capital-strategy-rain-protocol-tre-5921a627) — Source: Enlivex Therapeutics
- 2026-07-28 13:00 EST — [Enlivex Announces $400,000,000 Private Placement](https://biopharmsignal.com/news/ENLV/enlivex-announces-400-000-000-private-placement-20e71a7a) — Source: Enlivex Therapeutics
- 2026-07-20 13:00 EST — [Enlivex Treasury Portfolio Update: NAV Per Ordinary Share $66.16; Total Treasury Holdings Valued at Approximately $1.1 Billion](https://biopharmsignal.com/news/ENLV/enlivex-treasury-portfolio-update-nav-per-ordinary-share-66-16-total-treasury-ho-9d036ef9) — Source: Enlivex Therapeutics
- 2026-06-02 08:00 EST — [ENLIVEX TO PRESENT QUALITY LONGEVITY MODEL POWERED BY PREDICTION MARKETS TREASURY AT PROOF OF TALK 2026](https://biopharmsignal.com/news/ENLV/enlivex-to-present-quality-longevity-model-powered-by-prediction-markets-treasury-at-proof-of-talk-2026) — Source: Enlivex Therapeutics
- 2026-06-01 08:00 EST — [Allocetra Shows Durable 6-Month Efficacy in Knee Osteoarthritis Phase IIa Trial; Oral Presentation at EULAR 2026](https://biopharmsignal.com/news/ENLV/allocetra-shows-durable-6-month-efficacy-in-knee-osteoarthritis-phase-iia-trial-oral-presentation-at-eular-2026) — Source: Enlivex Therapeutics
## Related News
- 2026-07-29 14:05 EST — CAPR — [The Lancet Publishes HOPE-3 Data for Capricor Therapeutics’ Deramiocel in Duchenne Muscular Dystrophy](https://biopharmsignal.com/news/CAPR/the-lancet-publishes-hope-3-data-for-capricor-therapeutics-deramiocel-in-duchenn-9e6e6bd9)
- 2026-07-29 13:00 EST — ENLV — [Enlivex Management to Host Webinar to Discuss Capital Strategy, Rain Protocol Treasury Strategy, and Recent Clinical Milestones](https://biopharmsignal.com/news/ENLV/enlivex-management-to-host-webinar-to-discuss-capital-strategy-rain-protocol-tre-5921a627)
- 2026-07-29 12:30 EST — PRGO — [Perrigo to Present at the Canaccord 46th Annual Growth Conference](https://biopharmsignal.com/news/PRGO/perrigo-to-present-at-the-canaccord-46th-annual-growth-conference-40431922)
- 2026-07-29 12:30 EST — LIXT — [NOMAD Announces Operational Deployment of Two Mobile Battery Systems by DSO Electric Cooperative](https://biopharmsignal.com/news/LIXT/nomad-announces-operational-deployment-of-two-mobile-battery-systems-by-dso-elec-7fc12a2c)
- 2026-07-29 12:30 EST — RNXT — [RenovoRx to Host Second Quarter 2026 Financial Results and Business Highlights Conference Call on August 12th at 4:30 p.m. ET](https://biopharmsignal.com/news/RNXT/renovorx-to-host-second-quarter-2026-financial-results-and-business-highlights-c-8bed10ec)